SequelSEC

Whitehawk Therapeutics, Inc. WHWK

Pharmaceutical Preparations · CIK 0001422142 · Fiscal year ends 1231

Revenue
$7.14M
Fiscal year ended 2025-12-31
Operating income
-$114.40M
Fiscal year ended 2025-12-31
Free cash flow
-$97.98M
Fiscal year ended 2025-12-31

Whitehawk Therapeutics, Inc. (WHWK) reported revenue of $7.14M and net income of -$20.60M for the fiscal year ended 2025-12-31. This page shows 8 annual periods of income statement, balance sheet and cash flow figures normalized from Whitehawk Therapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Whitehawk Therapeutics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
Revenue$7.14M$25.98M$24.35M$15.22M$14.00M$14.00M$0$20.16M
Cost of revenue$760.00K$3.02M$2.81M$1.34M$0UnavailableUnavailableUnavailable
Gross profit$6.38M$22.96M$21.54M$13.88MUnavailableUnavailableUnavailableUnavailable
Operating income-$114.40M-$67.46M-$71.93M-$62.68M-$111.22M-$2.55M-$24.44M-$11.18M
Net income-$20.60M-$63.69M-$65.76M-$60.51M-$110.09M-$3.48M-$23.27M-$10.40M
Research & development$90.96M$51.03M$48.93M$32.66M$19.67M$15.01M$12.82M$17.85M
Weighted-average diluted sharesshares 61.89Mshares 27.03Mshares 26.92Mshares 22.51Mshares 8.92MUnavailableUnavailableUnavailable
Pretax income-$20.60M-$63.69M-$65.76M-$60.51M-$110.09M-$3.48MUnavailableUnavailable
Income tax expense$0$0$0$0$2.00K$2.00KUnavailableUnavailable
Diluted EPS$-0.33$-2.36$-2.44$-2.69$-12.41UnavailableUnavailableUnavailable
Selling, general & administrative$29.82M$36.75M$44.55M$40.18M$18.51MUnavailableUnavailableUnavailable
General & administrativeUnavailableUnavailableUnavailableUnavailable$18.51M$2.12M$9.76M$13.49M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Whitehawk Therapeutics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
Cash & equivalents$37.57M$28.67M$62.89M$39.02M$148.99M$4.46M$38.52M$62.61M
Total assets$150.83M$70.32M$132.42M$184.24M$157.91M$18.82M$39.94M$64.12M
Current assets$149.01M$61.29M$124.59M$180.03M$151.27M$18.68M$39.57M$63.98M
Total liabilities$14.52M$17.84M$27.23M$25.86M$21.50M$31.26M$3.40M$5.46M
Current liabilities$14.52M$17.07M$26.40M$18.84M$15.27M$30.06M$3.33M$5.46M
Total equity incl. NCI$136.31M$52.48M$105.20M$158.38M$136.41M-$12.43M-$9.09M$58.67M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$0$5.31M$6.43M$1.86M$0UnavailableUnavailableUnavailable
Accounts receivable$0$5.90M$5.49M$1.86M$0$14.15MUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$917.00K$2.16M$5.90M$3.52M$6.44M$2.39M$439.78K$595.68K

Cash flow

Whitehawk Therapeutics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
Operating cash flow-$97.43M-$59.55M-$59.66M-$49.64M-$22.42M-$12.70M-$23.85M-$5.81M
Capital expenditures$552.00K$1.65M$3.97M$444.00K$46.00K$19.02K$236.95K$37.91K
Investing cash flow$11.89M$25.20M$83.21M-$132.89M$25.15M-$19.02K-$236.95K-$37.91K
Financing cash flow$94.38M$130.00K$326.00K$72.62M$141.80M$1.19MUnavailable$48.20M
Net change in cash$8.83M-$34.22M$23.87M-$109.91M$144.53M-$11.51M-$24.09M$42.35M
Stock-based compensation$9.87M$10.84M$11.95M$9.64M$2.11M$139.00K$1.09M$3.43M
Common dividends paidUnavailableUnavailableUnavailable$0$4.41MUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$79.00K$193.00K$169.00K$159.00K$105.00K$9.00KUnavailableUnavailable

Derived

Whitehawk Therapeutics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
Free cash flow-$97.98M-$61.20M-$63.64M-$50.08M-$22.47MUnavailable-$24.09M-$5.85M
Gross margin89.4%88.4%88.5%91.2%UnavailableUnavailableUnavailableUnavailable
Operating margin-1601.1%-259.6%-295.4%-411.9%UnavailableUnavailableUnavailable-55.5%
FCF margin-1371.4%-235.6%-261.3%-329.2%UnavailableUnavailableUnavailable-29.0%
SBC / revenue138.2%41.7%49.1%63.4%UnavailableUnavailableUnavailable17.0%
Current ratio10.26x3.59x4.72x9.56x9.90x0.62x11.87x11.73x
Revenue YoY growth-72.5%6.7%60.1%8.7%0.0%Unavailable-100.0%Unavailable
Net margin-288.3%-245.1%-270.0%-397.7%UnavailableUnavailableUnavailable-51.6%
R&D / revenue1273.1%196.4%200.9%214.7%UnavailableUnavailableUnavailable88.6%
CapEx / revenue7.7%6.4%16.3%2.9%UnavailableUnavailableUnavailable0.2%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open WHWK in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-06View SEC filing
10-Q · Filed 2026-05-07View SEC filing
10-K · Filed 2026-03-12View SEC filing
10-Q · Filed 2025-11-06View SEC filing
10-Q · Filed 2025-08-07View SEC filing
10-Q · Filed 2025-05-08View SEC filing

Companies in the same industry

Reconciliation checks needing review

2 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

gross profit bridgeinconsistent2021-12-31

Withheld: gross profit could not be reconciled with the rest of this filer’s statement.

balance equationreview2019-12-31

Difference 45628343 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.